DE3277801D1 - Use of 4-aminosalicylic acid as an anti-inflammatory agent - Google Patents

Use of 4-aminosalicylic acid as an anti-inflammatory agent

Info

Publication number
DE3277801D1
DE3277801D1 DE8282810125T DE3277801T DE3277801D1 DE 3277801 D1 DE3277801 D1 DE 3277801D1 DE 8282810125 T DE8282810125 T DE 8282810125T DE 3277801 T DE3277801 T DE 3277801T DE 3277801 D1 DE3277801 D1 DE 3277801D1
Authority
DE
Germany
Prior art keywords
aminosalicylic acid
inflammatory agent
aminosalicylic
acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8282810125T
Other languages
English (en)
Inventor
Myron J Lover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stafford Miller Continental NV
Stafford Miller Ltd
Original Assignee
Stafford Miller Continental NV
Stafford Miller Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stafford Miller Continental NV, Stafford Miller Ltd filed Critical Stafford Miller Continental NV
Application granted granted Critical
Publication of DE3277801D1 publication Critical patent/DE3277801D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
DE8282810125T 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent Expired DE3277801D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/245,035 US4440763A (en) 1981-03-18 1981-03-18 Use of 4-aminosalicyclic acid as an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
DE3277801D1 true DE3277801D1 (en) 1988-01-21

Family

ID=22925050

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8282810125T Expired DE3277801D1 (en) 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent
DE1999175031 Active DE19975031I2 (de) 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1999175031 Active DE19975031I2 (de) 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Country Status (7)

Country Link
US (1) US4440763A (de)
EP (1) EP0062000B1 (de)
AT (1) ATE31243T1 (de)
AU (1) AU554443B2 (de)
CA (1) CA1194419A (de)
DE (2) DE3277801D1 (de)
LU (1) LU90386I2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (de) * 1980-03-20 1982-03-11
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
USRE33239E (en) * 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
AU1388388A (en) * 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
DE3839839A1 (de) * 1988-11-25 1990-05-31 Henning Berlin Gmbh Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
DE3924570A1 (de) * 1989-07-25 1991-01-31 Henning Berlin Gmbh Pharmazeutische zubereitung zur rektalen verabreichung
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
SE9000485D0 (sv) * 1990-02-09 1990-02-09 Pharmacia Ab Foamable composition for pharmaceutical use, use thereof and method of treatment
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AR012304A1 (es) * 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
RU2008152751A (ru) * 2006-06-06 2010-07-20 Антиб Терапьютикс Инк. (Ca) Соли тримебутина и n-десметилтримебутина
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US7645801B2 (en) * 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
NZ594310A (en) 2009-02-20 2014-02-28 To Bbb Holding B V Glutathione-based drug delivery system
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (de) 2013-06-04 2018-09-05 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von diabetes und prädiabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (de) 2015-01-06 2021-10-27 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von entzündungen und schmerzen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2639294A (en) * 1947-12-11 1953-05-19 Ferrosan Ab Method of producing nu-substituted derivatives of 4-amino-2-hydroxybenzoic acid
US2580195A (en) * 1948-01-31 1951-12-25 Ferrosan Ab Method of purifying 4-aminosalicylic acid
US2766278A (en) * 1951-08-10 1956-10-09 Rheinpreussen Ag 4-monoalkylaminosalicylic acids and 4-monoalkyloxyalkylaminosalicylic acids
US2711423A (en) * 1953-07-06 1955-06-21 American Cyanamid Co Neutral calcium 4-aminosalicylate hemihydrate and preparation of the same
US2874177A (en) * 1955-06-25 1959-02-17 Gohei Tanabe & Co Ltd Novel complex salt of 4-aminosalicylic acid and processes for producing the same
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
CA1194419A (en) 1985-10-01
EP0062000B1 (de) 1987-12-09
US4440763A (en) 1984-04-03
EP0062000A3 (en) 1983-07-27
AU8165982A (en) 1982-09-23
LU90386I2 (fr) 1999-06-24
ATE31243T1 (de) 1987-12-15
EP0062000A2 (de) 1982-10-06
DE19975031I2 (de) 2004-09-23
AU554443B2 (en) 1986-08-21

Similar Documents

Publication Publication Date Title
DE3277801D1 (en) Use of 4-aminosalicylic acid as an anti-inflammatory agent
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
NL191332C (nl) Farmaceutisch preparaat met de ethylester van (all-Z)-5,8,11,14,17-eicosapentaeenzuur.
IT8223892A0 (it) Composizione di antralina migliorata e suo uso nel trattamento di malattie della pelle.
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
DE2963572D1 (en) Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
NL187786C (nl) Injecteerbare oplossing van tetracycline in water; therapeutisch voorwerp.
ZA855224B (en) Pyrrol-1-ylphenyldihydropyridazinones,their preparation and their use
NL7804192A (nl) Cyclohexaancarbonzuur en de derivaten hiervan, evenals de toepassing van deze stoffen als therapeutisch mid- del.
IT8223309A0 (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
MX9704150A (es) Uso de l-carnitinas de alcanoilo para el tratamiento de enfermedades del intestino cronicas, inflamatorias.
IL65936A (en) Chloroacetic acid cyclohexylamides,their preparation and their use as herbicides
AU531314B2 (en) Therapeutic agent containing human urinary acid protease
IT7819623A0 (it) Composizione adatta alla purificazione del sangue e suoi impieghi.
ZA792554B (en) Pharmalceutical compositions for use in the treatment of diabetic nephropathy
JPS51119904A (en) Brush system of dc motor
JPS5238506A (en) Detergent composition
JPS57181041A (en) Novel nitrobenzoic acid derivative, manufacture and use
IL57838A0 (en) N-cyclohexyl-n-methoxyacetamide,its preparation and its use in the preparation of o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamic acid
JPS5213495A (en) Calcinfd plaster for extrusion molding
JPS5319790A (en) Electrochemical display body
HUT62447A (en) Composition disinfecting and indicating body paris
CA603219A (en) 5:5'-dinitro-2:2'-dichloro benzil
JPS52156823A (en) 2-phenoxymuconic acid and its preparation
IE800108L (en) Compositions for the treatment of psoriasis, skin cancers¹and oral and vaginal leukoplakia.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330

V457 Spc granted

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330

V464 Spc expired

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330